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INTRODUCTION
Analytical  techniques  hold  the  key  to  the  design,  development 
standardization and quality control of medical products.
They  are  equally  important  in  pharmacokinetics  and  in  drug 
metabolism studies,  both  of  which are  fundamental  to  the  assessment  of 
bioavailability and the duration of clinical response.
The various analytical techniques available are,
1. Gravimetric Analysis
2. Titrimetric Analysis
3. Volumetry 
4. Electrical Methods
5. Optical Methods
Spectroscopy:
It is the measurement and interpretation of electromagnetic radiations 
absorbed or  emitted  when the  molecules  or  atoms or  ions  of  the  sample 
undergo transition from one energy state (Ground state) to another (excited 
state).
It is two types,
1. Absorption Spectroscopy:
Where absorption of electro magnetic radiation (EMR) takes place.
(eg.) Colorimetry, UV spectroscopy, IR spectroscopy, etc.
2. Emission Spectroscopy:
Where emission of radiation is being studied.
(eg.) Fluorimetry, Flame Photometry.
Assay of Substances in Multi Component Samples:
There are
1. Simultaneous equation method
2. Absorbance ratio method
Simultaneous Equation Method:
If a sample contains two absorbing drugs (X and Y) each of which 
absorbes at the λmax of the other. It may be possible to determine the quantity 
of both drugs by the technique of simultaneous equation.     
Absorbance Ration Method:
This  method  depends  on the  property  of  a  substance  which  obeys 
Beer’s  law  at  all  wavelengths,  the  ration  of  absorbance  at  any  two 
wavelengths is a constant value independent of concentration or path length. 
Two different dilutions of the same sample give the same absorbance ratio; 
this ratio is referred to as a ‘Q’ value.
CHROMATOGRAPHY
Introduction:
Modern pharmaceutical formulations are complex mixtures containing 
one  or  more  therapeutically  active  ingredients.  The  most  powerful 
techniques available to the analyst for the separation of there mixtures,  a 
group  of  highly  efficient  methods  which  are  collectively  called  as 
chromatography.
It’s a group of technique which works on the principle of separation of 
components  of  a mixture into individual  components,  depending on their 
affinities for the solutes between two immiscible phases.
High Performance Liquid Chromatography:
The technique is based on the same modes of separation as classical 
column chromatography. i.e. adsorption, partition (including reversed-phase 
partition), ion exchange and gel permeation.
According to mode of separation, the stationary phase is polar and the 
mobile  phase  is  non-polar  is  called as  normal  phase  high performance 
liquid chromatography.
The stationary phase is  non-polar  and the mobile  phase is  polar  is 
called as reverse phase high performance liquid chromatography.         
AIM OF PRESENT WORK
The newer antiviral drugs in combined dosage form are selected for 
the analysis by high performance liquid chromatography method.
It should be more accurate, simple, rapid, efficient than other methods 
of analytical techniques.
Since, the combined dosage formulation can not be easily separated by 
other analytical technique like UV and other titrimetric analysis.
So, that I shall select this HPLC for the separation and estimation of 
newer anti viral combined dosage forms. It will be simple, rapid, efficient 
and reliable for the analysis of the drugs in combined dosage form.
Newer Combined Dosage Form of Anti Viral Drugs: 
1. Efavirence + Zidovudine + Lamivudine
2. Lopinavir + Ritonavir
3. Lamivudine + Zidovudine
4. Stavudine + Lamivudine
5. Nevirapine + Stavudine + Lamivudine
6. Nevirapine + Zidovudine + Lamivudine
DEVELOPMENT AND VALIDATION OF HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY OF NEWER ANTI VIRAL DRUGS 
IN COMBINED DOSAGE FORM
Method Development and Optimization:
Selection of Wavelength:
The known concentration of a Newer Anti Viral Drugs in Combined 
Dosage Form is taken dissolved in methanol. To fix the wavelength in the 
region  of  200  -400nm  and  the  wavelength  which  we  select  will  be  no 
fronting and tailing and the peak area is also found be minimum.
Selection of Mode of Operation:   
According to nature of drugs (polar / non-polar) the HPLC method 
will be selected. (Polar-RPHPLC, Non-polar-Normal phase HPLC) 
Selection and Standardization of Mobile Phase:
The mobile  phase  will  be selected  accordingly  which will  produce 
required adequate resolution of drug peaks in the chromatogram. 
Selection of Solvent System:
The peak of combined drug is well resolved with solvent system and 
buffer.
Selection of Flow Rate:
The  flow rate  for  combined  drug is  selected  should  not  show any 
fronting and tailing.
Preparation of Mobile Phase:
The  selected  buffer  and  solvent  system  is  mixed  together  in 
appropriate ratio and degass it.
Diluent:
Mobile phase used as diluent.
Determination of Retention Time:
The time at which the components are eluted to produce a peak.
Procedure:
Standard Solution of Drugs:
Accurately 100mg of standard drugs in combined dosage form was 
taken 100ml volumetric flask and the volume was adjusted to 100ml with 
mobile phase. From this 5ml is diluted to 50ml with mobile phase. 20μl of 
the solution injected and chromatogram is obtained. 
Preparation of Sample Solution:
Twenty  tablets  are  weighed  and  powdered.  Average  weight  is 
calculated. From this equivalent to 100mg is taken into 100ml volumetric 
flask. The powder was first dissolved in 20ml of mobile phase and sonicated 
and finally the volume was adjusted to 100ml with mobile phase. From this 
solution  5ml  was  transferred  to  50ml  volumetric  flask  and  volume  was 
adjusted  to  50ml  with  mobile  phase.  20μl  of  the  solution  injected  and 
chromatogram is obtained.
The amount of drugs present in the combined dosage formulation is 
calculated by comparing the peak area of standard.
Amount of drug present in the tablet =
Sample area x Standard dilution x Potency x Average Weight Standard area Sample dilution 100
Percentage Purity = Amount present x 100Label Claim  
VALIDATION
Method validation is the process of proving that an analytical method 
is  acceptable  for  its  intended  purpose.  For  pharmaceutical  methods, 
guidelines  from the  United  States  Pharmacopeia  (USP)  and  International 
Conference  on  Harmonization  (ICH).  In  general,  methods  for  regulatory 
submission must include studies on specificity, linearity, accuracy, precision, 
range, detection limit, quantitation limit, and robustness.
Design of Experiments:
Typical analytical parameters used in assay validation are,
 Specificity 
 Linearity and range
 Limit of quantification
 Limit of detection
 Accuracy
 Precision
⇒ System precision
⇒ Method precision
 Robustness
 Ruggedness
 System suitability studies
⇒ Resolution
⇒ Number of theoretical plates
⇒ The tailing factor 
SPECIFICITY
The  specificity  of  an  analytical  method  is  its  ability  to  measure 
accurately the analytes in the presence of compounds that may be expected 
to be presented to be present in the sample matrix.
Determination:
The specificity of the analytical method was determined by injecting 
the diluents or excipients solution under the same experimental conditions as 
the assay.
Procedure:
1. The excipients  of  dissolved in  mobile  phase  from this  20μl  of  the 
solution injected and chromatogram is obtained.  
2. The  excipients  along  with  standard  drugs  are  dissolved  in  mobile 
phase  from this  20μl  of  the solution injected  and chromatogram is 
obtained.
LINEARITY AND RANGE
Linearity of an analytical method is verified that the sample solutions 
are in a concentration range where analyte response is directly proportional 
to the concentration.
Determination:
The  linearity  of  analytical  method  was  determined  by  preparing  a 
linear  concentration  of  standard  mixture  solution.  20μl  of  the  solution 
injected and chromatogram is obtained. Area was plotted graphically as a 
function of drug concentration to get linear curve.   
Range:
It  is  the interval of lowest  concentration to largest concentration to 
give linear response. 
ACCURACY
The accuracy of an analytical method is the closeness of the results 
obtained by that method to the true value. Accuracy may often by expressed 
as percent recovery by the assay of known added amount of analyte.
Determination:
The accuracy of the analytical method was determined by applying the 
method to the analysed samples to which known amounts of analyte had 
been  added.  The  accuracy  was  calculated  from  the  test  results  as  the 
percentage of analyte recovered by the assay.
Acceptance Criteria:
Percentage recovery should be within 98-102% at each concentration 
over the range of 80-120%.
Procedure:
Mixed  standard  stock  solution  2ml  and  sample  stock  solution  2ml 
were mixed together in 50ml volumetric  flask and the volume was made 
upto  50ml  with  mobile  phase  to  get  80%  range.  Similarly  100%  (2ml 
standard + 3ml sample) and 120% (2lm standard + 4ml sample). 20μl of the 
solution injected 3 times and chromatogram is obtained.
PRECISION
Precision of an analytical method is the degree of agreement among 
individual test results when the procedure is applied repeatedly to multiple 
sampling of a homogenous sample. 
Determination:
The precision of the analytical method was determined by assaying 
sufficient number of sample and relative standard deviation was calculated.
Acceptance Criteria:
The relative standard deviation should be with in 2%.
System Precision:
The  system  precision  was  evaluated  by  measuring  6  successive 
injection of 20μl of  standard solution.  The peak response were measured 
from the chromatogram. 
Method Precision:
The  method  precision  was  evaluated  by  measuring  6  successive 
injection of 20μl of sample solution. The peak response were measured from 
the chromatogram.
LIMIT OF DETECTION (LOD)
It is the lowest amount of analyte in a sample that can be detected but 
not necessarily quantities as an exact value under the stated, experimental 
conditions. The detection limit is usually expressed as the concentration of 
analyte.
LOD = 3.3 x σm
σ - Standard deviation of the response 
m - Slope of the calibration curve
LIMIT OF QUANTITATION (LOQ)
The Quantitation limit of an analytical procedure is the lowest amount 
of analyte which can be Quantitatively determined with suitable Precision 
and Accuracy. 
LOQ = 10 x σm
σ - Standard deviation of the response 
m - Slope of the calibration curve
RUGGEDNESS
The ruggedness of an analytical method is degree of reproducibility of 
test result obtained by the analysis of the same sample under a variety of 
normal  test  condition,  such  as  different  laboratories,  different  analyst, 
different instruments, different lots of reagents, different elapsed assay times, 
different assay temperature, different days, etc.
ROBUSTNESS
Robustness  of  an  analytical  method  is  measure  of  its  capacity  to 
remain unaffected by small but deliberate variations in method parameters 
and provides an indication of its reliability during normal usage.
Determination:
The robustness of an analytical method was determined by analysis of 
aliquots from homogenous lots by differing physical parameters  that may 
differ but were still within the specified parameter of the assay for example 
change in physical parameters like flow rate, pH and lambda max.
SYSTEM SUITABILITY TESTING
It is an integral part of many analytical procedure. The tests of based 
on  the  concept  that  the  equipment,  electronics,  analytical  operations  and 
sample to be analyzed constitute an integral system that can be evaluated as 
such. 
The parameters are, 
1. Resolution:     
R = 2 (Rt2 – Rt1)W2 + W1
Where,
Rt1 and Rt2 = Retention time of two component
W1 and W2 = The respective peak width 
Acceptance Criteria:
It always >1.
2. Tailing Factor:
Fronting is due to saturation of stationary phase and can be avoided by 
using less quantity of sample. Tailing is due to more active adsorption sites 
and can be eliminated by support pretreatment, more polar mobile phased 
increasing the amount of liquid phase.
T = Yx2A
Where,
T - Tailing Factor
Yx - The width of the peak at one twentieth of the peak height 
A - The distance between the perpendicular dropped from the peak 
maximum and the leading edge of the peak at one twentieth of 
the peak height. 
3. Number of Theoretical Plates: 
N = 5.54 x Rt
 2
Wh/2
Rt - Retention Time
Wh/2 - Width of peak at half height
I shall complete this research project work with in Three years
DRUG PROFILE
Drug Name : Zidovudine
Structure
Chemical Name : 3’-Azido-3’ deoxythymidine
Molecular Formula : C10H13N5O4
Molecular Weight : 267.2
Description : A white to yellowish crystalline powder
Solubility : Sparingly soluble in water freely soluble in 
methanol, hot water ethanol
Therapeutic Category : Antiviral / Nucleoside reverse transcriptase 
inhibitor 
 DRUG PROFILE
Drug Name : Stavudine
Structure
Chemical Name : 2’3’-Didehydro-3-deoxy-thymidine
Molecular Formula : C10H12N2O4
Molecular Weight : 224.2
Description : White to off – white crystalline powder
Solubility : Freely soluble in methanol, distilled water 
Therapeutic Category : Antiviral / Nucleoside reverse transcriptase 
inhibitor 
DRUG PROFILE
Drug Name : Lamivudine 
Structure
Chemical Name : (2R Cis) 4 Amino-1-[2-(hydroxymethyl) –
1,3 oxathiolan -5-y;] -2 (lH)- pyrimidinone
Molecular Formula : C8H11N3O3S
Molecular Weight : 229.3
Description : White to off – whit crystals 
Solubility : Freely soluble in distilled water, ethanol  
slightly soluble in ethyl acetate 
Therapeutic Category : Antiviral / Nucleoside reverse transcriptase 
inhibitor 
     
DRUG PROFILE
Drug Name : Nevirapine
Structure
Chemical Name : 1-cyclopropyl-5, 11-dihydro-4-methyl-6H –
dipyrido [3,2-b:2’, 3’-e][1,4] diazepin-6-one
Molecular Formula : C15H14N4O
Molecular Weight : 266.298
Description : White to off – white crystalline powder
Solubility : Freely soluble in methanol, distilled water 
Therapeutic Category : Antiviral / Nucleoside reverse transcriptase 
inhibitor 
DRUG PROFILE
Drug Name : Efavirenz
Structure
Chemical Name : 8-chloro-5-(2-cyclopropylethynyl)-5-
(trifluoromethyl)-4-oxa-2-azabicyclo  [4.4.0] 
deca-7,9,11-trien-3-one
Molecular Formula : C14H9ClF3NO2
Molecular Weight : 315.675
Description : White to off – white crystalline powder
Solubility : Freely soluble in methanol, distilled water 
Therapeutic Category : Antiviral / Nucleoside reverse transcriptase 
inhibitor 
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Radha  Krishna  T.Raods et  al,  High  performance  liquid 
chromatographic and micellar electrokinetic chromatographic methods have 
been developed for the determination of pioghitazone hydrochloride in bulk 
and acetonitrle: Buffer in the ration of 50:50, as mobile phase. The pH is 
adjusted to 6 using O-phosphoric acid.
Sripalakit et al, High performance liquid chromatography with ultra 
violet  detection  (269nm)  was  developed  for  the  determination  of 
pioglitazone  in  human  plasma.  Rosiglitazone  was  used  as  an  internal 
standard. The separation was achieved with a RP-HPLC, a mobile phase of 
methanol:  Acetonitrile:  Buffer  (pH 2.6, 40:12:48 v/v/v)  with flow rate of 
1.2ml/  min.  The  linearity  range  of  50-2000ng/ml  and  the  lower  limit  of 
quantification was 50ng/ml.
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electroscopy ionization tandem MS method for simultaneous determination 
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internal standard has been first developed and validated. The separation was 
achieved by using a mobile phase methanol : 30mn ammonium acetates pH 
5.0 (80:20 v/v) delivered at 0.2ml/min.
D.Bhavesh et al, Estimated a simple and rapid HPLC assay method 
for  the  stimation  of  metformin  in  human  plasma  was  developed  and 
validated. The separation was achieved with a cationic exchange coloumn 
with  mobile  phase  of  methanol  :  pot  dihydrogen  ortho  phosphate  buffer 
(0.1m,  pH  3.5)  mixture  46:54%  v/v.  Detection  was  by  UV  detector  at 
236nm. The response was linear over a range of 30-5000ng/ml.
Dr.Harising Gowr et al, Performed a rapid and simple simultaneous 
estimation  of  metformin  and  gliclazide  in  combined  dosage  forms  by 
simultaneous  equation  at  two  wavelengths  corresponding  to  226.3  and 
233.2nm. Both the drugs are obey Beer’s law in the concentration ranges 
employed  for  this  method.  The  result  of  analysis  have  been  validated 
statistically and by recovery studies. 
Madhira B, Shankar et al, Performed spectrophotometric analysis of 
pioglitazone  hydrochloride  and  metformin  hydrochloride  in  combined 
dosage  forms  were  developed  using  second  derivative  spectrophotometry 
and RP-HPLC. In the LC method, analysis was performed on a C18 column, 
using the mobile phase acetonitrile – water – acetic acid (75:25:0.3) adjusted 
to pH 5.5 with liquid ammonia, at a flow rate of 0.5ml/min. The retention 
times were 8.5min for PIO, 16min to MET. The concentration range of 4-
20μg/ml for P10 and MET. The methods are validated results were compared 
statistically.
Bhaskar  Laxmanrao  Klte et  al,  Performed  simultaneous 
determination of metformin and glimepride in pharmaceutical dosage form 
by  RP-HPLC.  Under  the  developed  conditions,  good  separation  of  the 
analytes was achieved in short analysis time. The method is validated and 
shown to be linear in the range of 25-150μg/ml for metformin and 0.1μg/ml 
to 0.6μg/ml for glimepride.
A.Ghassempour et al, Estimated simultaneous determination of two 
antidiabetic  drugs  metformin  and  glyburide  in  pharmaceutical  tablet 
formulation  were  investigated.  Normal  phase  thirl  layer  chromatography 
(silica  gel  60  F254)  was  used  as  stationary  phase  and  water:  methanol: 
ammonium  sulfate  (2:1:0.5w/v)  as  mobile  phase  to  determine  two 
pharmaceutically  active  ingredients,  in  three  different  formulations.  This 
system gave a good resolution for metformin Rf 0.43 + 0.01 and glyburide 
Rf 0.64 + 0.02. The absorbance mode was selected at 237nm. The limit of 
detection and quantification were 25.24 and 84.12ng/spot for metformin and 
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Annapurna  M,  developed  spectrophotometric  estimation  of 
metformin hydrochloride in pharmaceutical dosage forms.
Cum-Gangding et  al  Developed  a  selective  sensitive  high 
performance  liquid  chromatography  for  simultaneous  determination  of 
metformin  and  glipizide  in  human  plasma,  has  been  developed  for 
simultaneous  quantification  of  metformin  and glipizide  in  human  plasma 
phenformin anf gliclazide were used as internal standards for metformin and 
glipizide respectively. The MS detection was performed in multiple reaction 
monitoring mode. The method was validated in the concentration ranges of 
0.02-4μg/ml and 0.004-0.8μg/ml for metformin and glipizide respectively.
Shankar,  Modi et  al,  Performed  spectrophotometric  and  liquid 
chromatographic methods for  simultaneous estimation of pioglitazone and 
metformin  hydrochloride  in  tablet  formulation.  The  pioglitazone  and 
metformin  in  combined  preparation  were  quantified  using  the  second 
derivative  responses  at  227.5nm  for  pioglitazone  and  257.25nm  for 
metformin  in  spectra  of  their  solutions  in  a  minture  of  methanol  and 
acetonitrile. The calibration cusves were linear in the concentration range of 
8-40μg/ml for PID and 4-12μg/ml for MET.
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with 5 micron particle size using the mobile phase acetonitrile: water: acetic 
acid (75+25+0.3) adhusted to pH 5.5 with liquor ammonia,  and flow rate 
0.5nl/min. Measurement was made at a wavelength of 230nm.
M.Vasudevan et  al  Developed a  simple  precise  and accurate  high 
performance  liquid  chromatography  for  the  simultaneous  estimation  of 
metformin, gliclazide and glizide present in multicomponent dosage forms. 
A  mobile  phase  composed  of  acetonitrile  water  containing  camphor 
sulphonic acid (adjusted to pH 7 using N/10 sodium hydroxide; 75mm) at a a 
flow  rate  1ml/min  used  for  the  separation.  Detection  was  carried  out  at 
225nm,  tolbutamide  was  used  as  internal  standard  validation  of  the 
developed HPLC method was carried out.
Mistri  HN et  al,  Performed  liquid  chromatography  tandem  mass 
spectrornetry  method  for  simultaneous  quantitation  of  antidiabeitc  drugs 
metformin  and  glyburide  in  human  plasma  using  glimepride  as  internal 
standard. Metformin, glyburide and internal standard were chromatographed 
on RP-C18 column. Quantization was performed on a triple quadrcepole mass 
spectrometer  employing  electroscopy  ionization  technique.  The  total 
chromatographic  run time  was 3.5min and calibration curves  were  linear 
over  the 20-2500ng/ml  for  metformin and 5-500ng/ml  for  glyburide.  The 
method was calidated for selectively, recovery specificity linearity precision 
and stability studies.
Zhang  Z,  Chen Y et  al  Developed  a  selective  and sensitive  high 
performance  liquid  chromatography  for  simultaneous  estimation  of 
metformin  and  rosiglitazone  in  human  plasma.  The  mobile  phase  was 
methanol  :  Ammonium  acetate  (80:20)  pH  adjusted  to  5  used  and  the 
retention time delivered at 0.2ml/min.
Anna  berecka et  al,  Performed  a  new  simple,  rapid  and  stability 
indicating high performance thin layer  chromatographic  method has been 
developed and validated  for  the  determination  of  rosiglitazone in  tablets. 
Analysis was performed on silica gel 60F254 plates in horizontal chambers 
with chloroform : wthyl acetate : 25% ammonium hydroxide (5:5:0.1) The 
calibration plots were constructed in the range of 0.2-1μg/10μl.
Ramesh  T.Sane et  al,  Estimated  a  high  performance  thin  layer 
chromatographic  method  has  been  developed  for  the  determination  of 
rosiglitazone  in  pharmaceutical  preparations.  This  method  uses  silica  gel 
60F254 as  the  stationary  phase,  ethyl  acetate  :  Toluene  :  Methanol 
(45:55:1v/v)  as  mobile  phase.  Detection  was  performed  at  242nm  and 
pioglitazone hydrochloride was used as internal standard. The method was 
validated to determine its accuracy and precision.
Kolte  BL,  et  al  develop  a  simple,  rapid,  and  precise  method  is 
developed for the quantitative simultaneous determination of metformin and 
pioglitazone  in  a  combined  pharmaceutical  dosage  form.  Separation  is 
achieved with a zorbax XDB C(18), 15cm analytical column using buffer 
acetonitirle (66:34, v/v) of pH 7.1, adjusted with orthophosphoric acid as the 
mobile phase. The buffer used in the mobile phase contains 10mm dospdium 
hydrogen phosphate and 5mm sodium dodecyl sulphate in double-distilled 
water.  The  instrumental  settings  are  flow  rate  of  1ml/min,  column 
temperature  at  40  degrees  C,  and  detector  wavelength  of  226nm.  The 
correlation  coefficients  for  metformin  an  dpioglitazone  are  0.9991  and 
0.9999,  respectively.  The  relative  standard  deviations  for  six  replicate 
measurements in two sets of each drug in the tablets are always less than 2%.
Radhakrishna  T,  et  al,  performed  high  performance  liquid 
chromatographic  (HPLC)  and  Micellar  Electrokinetic  Chromatographic 
(MEKC)  methods  have  been  developed  for  the  determination  of 
pioglitazone, a new englycemic antidiabetic agent. The MEKC method was 
compared with HPLC method using a 5 microm symmetry C18 column (250 
x 4.6mm id.) eluted with a mobile phase consisting of a mixture of 50% (v/v) 
acetonitrile and 10mm potassium dihydrogen phosphate buffer, adjusting the 
pH to 6.0 with 0.1m KOH. The HPLC method is capable of detecting all 
process related compounds, which may be present at trace levels in finished 
products. Both methods were fully validated and a comparison was made.
Khan  MA,  et  al  developed  five  impurities  in  glimepiride  drug 
substance  were  detected  and  quantified  using  a  simple  isocratic  reverse 
phase  HPLC method.  For  the  identification  and  characterization  purpose 
these impurities were isolated from a crude reaction mixture of glimepiride 
using a normal phase HPLC system. The chromatographic separation was 
achieved on a phenomenex luna C8 (2) 100A, 5 microm, 250mm x 4.6mm 
using a mobile phase consisting of phosphate buffer (pH 7.0) acetonitrile – 
tetrahydrofurna (73:18:09, v/v/v) with UV detection at 228nm and a flow 
rate of 1ml/min. the column temperature was maintained at 35 degrees C 
through out the analysis. The method has been validated as per international 
guidelines  on  method  validation  and  can be  used  for  the  routine  quality 
control analysis of glimepiride as active pharmaceutical ingredient (API).    
Dubey A; Shukla IC,  et al estimated a new HPLC method for the 
determination of glipizide and metformin hydrochloride in combination. The 
method is based on reverse phase liquid chromatography using C18 column 
and a suitable mobile phase. The detection is done at 225nm. The flow rate is 
adjusted at 1.0ml/min. and the linearity is established.
Zarapkar SS; Salunkhe BB, et al performed a high performance thin 
layer chromatographic method for the determination of glipizide in tablets is 
described.
Pak  J  Pharm  Sci et  al,  performed  the  reversed  phase  high 
performance  liquid  chromatographic  (RP-HPLC)  method  has  been 
developed to quantify metformin hydrochloride (MFCI) in raw material and 
pharmaceutical  formulations  using  C18  analytical  reverse  phase  column. 
Diazepam  was  used  as  an  internal  standard.  Mobile  phase  consisted  of 
methanol water (30:70 v/v), pumped at a flow rate of 0.5ml/min at ambient 
temperature  and  the  retention  time  was  about  4.4min  with  symmetrical 
peaks.  (MFCI)  was detected by ultraviolet  absorbance  at  233nm with no 
interference of commonly used excipients. The method was linear over the 
concentration range 0.312-5μg/ml (R2 = 0.9995). The limit of detection of 
metformin was 0.1μg/ml  and the limit  of quantitation was 0.3μg/ml.  The 
results obtained showed a good agreement with the declared contents in case 
of  pharmaceutical  formulations.  The  proposed  method  is  rapid,  accurate, 
economical and selective and it may be used for the quantitative analysis of 
metformin.
R.T.Sane, S.N.Menon, et al, performed a rapid and accurate HPLC 
method has been developed for simultaneous determination of pioglitazone 
and  glimepiride.  Chromatographic  separation  of  the  two  pharmaceuticals 
was performed on a Cosmosil C18 column (150mm x 4.6mm, 5μm) with a 
45:35:20 (v/v) mixture of 0.01m triammonium citrate (pH adjusted to 6.95 
with orthophosphoric acid), acetonitrile, and methanol as mobile phase, at 
228nm.  Separation  was  complete  in  less  than  10min.  The  method  was 
validated  for  linearity,  accuracy,  precision,  limit  of  quantitation,  and 
robustness. Linearity over the ranges 2.50-30.00μg/ml-1 for pioglitazone and 
0.10-10.00μg/ml-1 for glimepiride.    
Radhakrishna T, Sreenivas Rao D, et al, worked a high performance 
liquid  chromatographic  (HPLC)  and  Micellar  Electrokinetic 
Chromatographic  (MEKC)  methods  have  been  developed  for  the 
determination  of  pioglitazone,  a  new englycemic  antidiabetic  agent.  20% 
acetonitrile (v/v) in 20mm sodium borate buffer pH 9.3 containing 50mm 
sodium dodecyl sulphate (SDS). HPLC method using a 5 microm symmetry 
C18 column (250 x 4.6mm i.d.) eluted with a mobile phase consisting of a 
mixture  of  50%  (v/v)  acetonitrile  and  10mm  potassium  dihydrogen 
phosphate  buffer,  adjusting  the  pH  to  6.0  with  0.1m  KOH.  The  results 
confirm that the methods are highly suitable for its intended purpose.
Kolte B.L. Raut B.B., et al performed a simple, rapid, and precise 
method  is  developed  for  the  quantitative  simultaneous  determination  of 
metformin  and  pioglitazone  in  a  combined  pharmaceutical  dosage  form. 
Separation is achieved with a Zorbax XDB C18, 15cm analytical column 
using  buffer  acetonitrile  (66:34,  v/v)  of  pH  7.1,  adjusted  with 
orthophosphoric acid as the mobile  phase.  The buffer  used in the mobile 
phase  contains  10mm  disodium  hydrogen  phosphate  and  5mm  sodium 
dodecyl sulphate in double distilled water. The instrumental settings are flow 
rate of 1ml/min,  column temperature at 400C, and detector wavelength of 
226nm.  The  internal  standard  method  is  used  for  the  quantitation  of  the 
ingredients of this combination. The method is validated and shown to be 
linear for metformin and pioglitazone are 0.9991 and 0.9999, respectively. 
The relative standard deviations for six replicate measurements in two sets of 
each drug in the tablets are always less than 2%.
Lin Z.J, Ji W, Desai-Krieger D, Shum L. et al, performed a liquid 
chromatography  /  tandem  mass  spectrometry  (LC-MS/MS)  method  was 
developed and validated for the simultaneous determination of pioglitazone 
(PIO) and its two metabolites. The compounds were eluted isocratically on a 
C18 column, ionized using a positive ion atmospheric pressure electrospray 
ionization  source  and analysed using multiple  reaction  monitoring  mode. 
The chromatographic run time was 2.5min per injection, with retention times 
of  1.45,  1.02  and  0.95  min  for  PIO,  M-III  and  M-IV,  respectively.  The 
calibration curves of pioglitazone, M-III and M-IV were well fit over the 
range  of  0.5-2000ng/ml  (r(2)>0.998759)  by  using  a  weighted  (1/x(2)) 
quadratic regression. The method is simple, rapid and rugged, and has been 
applied successfully to sample analysis for clinical studies.
Yamashita  K,  Murakami  H,  et  al  estimated  a  high  performance 
liquid chromatographic (HPLC) method for the simultaneous determination 
of pioglitazone and its metabolites (M-I to M-V) in human serum and urine 
was developed. The method for serum involved the solid-phase and liquid-
liquid  extraction.  Urine  with  and  without  enzymatic  hydrolysis  using 
betaglucuronidase was treated with liquid –liquid extraction. The compounds 
in the extract were analyzed using HPLC with UV detection at 269nm. The 
detection limits of pioglitazone, M-I, M-II, M-III, M-IV, and M-V in serum 
were 0.01-0.05 micrograms/ml, those in urine were 0.3-0.5 micrograms/ml, 
respectively. The method was applied to the clinical trials of pioglitazone.
Isam  Ismail  Salem et  al  estimated  a  sensitive  and  specific  high-
performance liquid chromatography – electrospray ionization –tandem mass 
spectrometry (HPLC-ESI-MS-MS) method has been developed at our center 
for the determination of glimepiride in human plasma. The compounds were 
separated  on  a  prepacked  C18  column  using  a  mixture  of  acetonitrile, 
methanol  and  ammonium  acetate  buffer  as  mobile  phase.  Linearity  was 
established for the range of concentrations 5.0-500.0ng/ml with a coefficient 
of  determination  (r2)  of  0.9998.  Accuracy  for  glimepiride  ranged  from 
100.58 to 104.48% at low, mid and high levels. The intra-day precision was 
better than 12.24%. The lower limit of quantitation (LLOQ) was identifiable 
and reproducible at 5.0ng/ml with a precision of 7.96%.
Gomes-P;  Sippel-J,  Jablonski-A;  Steppe-M et  al  developed  a 
method for the determination of rosiglitazone (Avandia) in coated tablets is 
described  Micellar  electrokinetic  chromatographic,  and  high  performance 
liquid chromatographic methods are employed.
Radhakrishna-T,  Satyanarayana-J;  Satyanarayana-A et  al 
estimated  an  isocratic  reversed  phase  liquid  chromatographic  (RP-LC) 
method has been developed and subsequently validated for the determination 
of rosiglitazone and its related impurities. Separation was achieved with a 
Symmetry C18 column and sodium phosphate buffer (pH adjusted to 6.2): 
acetonitrile (50:50, v/v) as eluent, at a flow rate of 1.0ml/min. UV detection 
was  performed  at  245  run.  The  method  is  simple,  rapid,  selective  and 
stability indicating. Indole was used as internal standard for the purpose of 
quantification of rosiglitazone. The described method is linear over a range 
of  0.45-10mug/ml  for  related impurities  and 180-910mgu/ml  for  assay of 
rosiglitazone.  The  method  precision  for  the  determination  of  assay  and 
related compounds was below 1.0 and 3.6% RSD, respectively. The means 
recoveries  of  impurities  were found to be  in  the  range of  95-102%. The 
percentage  recoveries  of  Active  Pharmaceutical  Ingredient  (API)  from 
dosage forms ranged from 99.02 to 101.30.
Sripalakit  P,  Neamhom  P,  et  al  performed  an  analytical  method 
based on high-performance liquid chromatography (HPLC) with ultraviolet 
detection (269nm) was developed for the determination of pioglitazone in 
human  plasma.  Rosiglitazone  was  used  as  an  internal  standard. 
Chromatographic separation was achieved with a reversed phase Apollo C18 
column and a mobile phase of methanol acetonitrile mixed phosphate buffer 
(pH  2.6;  10mm)  (40:12:48,  v/v/v)  with  a  flow  rate  of  1.2ml/min.  The 
calibration curve was linear over the range of 50-2000ng/ml (r(2)>0.9987) 
and the lower limit of quantification was 50ng/ml. The method was validated 
with excellent sensitivity, accuracy, precision, recovery and stability.
Jaafar I, A.L.Tamini et al developed a thin-layer chromatographic 
behavior  of  new  oral  antidiabetic  drugs,  pioglitazone,  rosiglitazone,  and 
repaglinide  has  been  investigated.  Mobile  phases  comprising  1,4-dioxane 
with  phosphate  buffers  were  used.  Then,  a  simple,  rapid,  and  stability-
indicating  high performance  thin-layer  chromatographic  method  has  been 
developed and validated for the quantitative determination of ioglitazone in 
tablets.  Analysis was performed with 1,4-dioxane-phosphate buffer  of pH 
4.4 (5:5) as the mobile phase. Detection and quantification were performed 
by  classical  densitometry  at  the  wavelength  of  maximum  absorption  of 
pioglitazone, 266nm. A calibration plot was constructed in the range of 0.4-
2.4μg/10μl and was linear with a good correlation coefficient (r = 0.9957). 
Precision  was  validated  by  replicate  analyses  of  standard  solutions,  and 
accuracy by analysis of fortified samples.
Radhakrishna-T,  Rao-DS,  Reddy-Go et  al  performed  high 
performance  liquid  chromatographic  (HPLC)  and  Micellar  Electrokinetic 
Chromatographic  (MEKC)  methods  have  been  developed  for  the 
determination  of  pioglitazone,  a  new  englycemic  antidiabetic  agent.  The 
MEKC method was compared with HPLC method using a 5mum symmetry 
C18 column (250 x 4.6mm W.) eluted with a mobile phase consisting of a 
mixture  of  50%  (v/v)  acetonitrile  and  10mm  potassium  dihydrogen 
phosphate  buffer,  adjusting  the  pH to  6.0  with  0.1  M KOH. The HPLC 
method  is  capable  of  detecting  all  process  related  compounds,  which 
comparison was made.
S.Vijaya Saradhi et al performed a reverse phase high pressure liquid 
chromatographic method has been described for the estimation of glipizide 
in  its  pharmaceutical  formulations  using  C8  column.  The  mobile  phase 
consisted  of  acetonitrile,  methanol  and buffer  (7.0ml  of  triethyl  amine  in 
1000ml of water, pH adjusted to 3.0 + 0.1 with orthophisphoric acid) in the 
ration of 35:50. The detection was carried out at 230nm and the linearity was 
found to be in the range of 0.1 to 10μg/ml. The method is simple, precise, 
specific, less time consuming and accurate for the estimation of glipizide in 
pharmaceutical dosage forms.
Puranik M, Wadher S.J., et al performed two simple, accurate and 
reproducible  spectrophotometric  methods,  requiring  no  prior  separation, 
have  been developed for  the  simultaneous  estimation  of  metformin  HCL 
(MET) and Rosiglitazone meleate  (ROSI) in combined dosage form.  The 
first method employs formation and solving of simultaneous equations using 
237 and 247nm as the two wavelength for forming equations. The second 
method  is  the  absorption  correction  method  using  237  and  283nm  and 
methanol as solvent and linearity lies between 0-50mcg/ml. for metformin 
and Rosiglitazone at their respective wavelength.
S.B.Wankhede et al, developed a new validated reverse phase high 
performance liquid chromatographic method for simultaneous estimation of 
telmisartan and hydrochlorothiazide in tablet formulation. Chromatography 
was performed on a ODS Hypersil C18 (25cm x 4.6mm I.D) column from 
thermo in isocratic mode with mobile phase containing acetonitrile : 0.05 M 
KH2PO4pH3.0  (60:40).  The  flow rate  was  1.0ml/min  and  the  eluent  was 
monitored at 271nm. The selected chromatographic conditions were found to 
effectively separate telmisartan (RT-5.19min) an dhydrochlorothiazide (RT-
2.97min). Linearity for telmisartan and hydrochlorothiazide were found in 
the range of 4.1-20.48μg/ml and 1.28-6.4μg/ml, respectively. The proposed 
method was found to be accurate, precise, reproducible and specific and can 
be used for simultaneous analysis of these drugs in tablet formulation.
Giuseppe Carlucci et  al  developed a  method  for  the simultaneous 
determination  of  losartan  potassium and hydrochlorothiazide  in  tablets  is 
described.  The  procedure,  based  on  the  use  of  reversed  phase  high 
performance liquid chromatography is linear in the concentration range 3.0-
7.0μg/ml-1 for losartan and 0.5-2.0μg/ml-1 for hydrochlorothiazide, is simple 
and rapid and allows accurate and precise results. The limit of detection was 
0.08μg/ml-1 for losartan and 0.05μg/ml-1 for hydrochlorothiazide.                 
Lande N.R., Shetkar B.M., Kadam S.S and Dhaneshwar S.R et al 
estimated two simple accurate and economical procedures for simultaneous 
estimation  of  Losartan  Potassium  and  Hydrochlorothiazide  in  two 
component tablet formulations have been developed. The method employs 
simultaneous equations and Q-analysis.  In all  glass  double distilled water 
Losartan  Potassium  has  an  absorbance  maxima  at  205nm, 
hydrochlorothiazide has three absorbance maximas  at  225nm,  272nm and 
315nm.  Both  drugs  obey  the  Beer’s  Law  in  the  concentration  ranges 
employed for  these methods.  The results  of  analysis  have been validated 
statistically and by recovery studies.
Nevin Erk et al performed a new simple, precise, rapid and selective 
reversed phase high performance liquid chromatographic (HPLC) and two 
spectrophotometric  methods.  The  first  method,  is  based  on  HPLC  on  a 
reversed  phase  column  using  a  mobile  phase  0.01N  sodium  dihydrogen 
phosphaye : methanol : acetonitrile (8:2:1 v/v/v) (pH 5.5) with detection at 
265.0nm.  The  second  method,  is  depend  on  ration  derivative 
spectrophotometry, the amplitudes in the first derivative of the ration spectra 
at 238.360nm and at 230.423nm. The third method, based on compensation 
technique is presented for the derivative spectrophotometric determination of 
binary mixtures with overlapping spectra.
Farthing D, Fakhry I,  et  al  performed a simple high performance 
liquid  chromatographic  (HPLC)  method  utilizing  narrowbore 
chromatography was developed for the determination of hydrochlorothazide 
in human urine. A mobile  phase of 0.1% aqueous acetic acid acetonitrile 
(93:7,  v/v)  pH 3 was  used with a  C18 analytical  column and ultraviolet 
detection  (UV).  The  method  was  utilized  in  a  study  evaluating  if  racial 
differences are present in the pharmacokinetic and pharmacodynamic effects 
of hydrochlorothiazide.
Wankhede  SB,  Tajne  MR et  al  validated  reverse  phase  high 
performance liquid chromatographic method for simultaneous estimation of 
telmisartan and hydrochlorothiazide in tablet formulation. Chromatography 
was performed on a ODS Hypersil C18 (25cm x 4.6mm I.D) column from 
thermo in isocratic mode with mobile phase containing acetonitrile: 0.05 M 
KH2PO4 pH3.0 (60:40).  The flow rate was 1.0ml/min and the eluent was 
monitored  at  271nm.  The  proposed  method  was  found  to  be  accurate, 
precise, reproducible and specific and can be used for simultaneous analysis 
of these drugs in tablet formulation.
Loannis Niopas et al developed a simple, specific, sensitive, precise, 
and  accurate  high  performance  liquid  chromatography  procedure  was 
developed and validated for the analysis of hydrochlorothiazide in human 
plasma. Separated on a reversed phase column with acetonitrile/water 0:80, 
v/v as the eluent. Peaks were monitored at 271nm. The method was found to 
be linear in the 5 to 80ng/ml concentration range (r<0.999). The limit  of 
quantitation was found to be 5ng/ml for 1ml plasma samples.
Nevin  Erk et  al  estimated  two new methods  for  the  simultaneous 
determination of valsartan and hydrochlorothiazide in pharmaceutical dosage 
forms  have  been  developed.  The  first  method,  based  on  compensation 
technique is presented for the derivative spectrophotometric determination of 
binary mixtures with overlapping spectra. By using ratios if the derivative 
maxima  or  the  derivative  minimum,  the  exact  compensation  of  either 
component in the mixture can be achieved, followed by its determination. 
The second method, differential derivative spectrophotometry comprised of 
measurement of the difference absorptivities derivatized in the first order of 
a tablet extract in 0.1 N NaOH relative to that of an equimolar solution in 
methanol at wavelengths of 227.8 and 276.5nm, respectively. The proposed 
methods were accurate, sensitive, precise, reproducible and could be applied 
directly and easily to the pharmaceutical preparations.
Deanne L. Hertzog et al estimated a new class of potent angiotensin 
II  receptor  antagonists  which  are  well-tolerated  in  the  treatment  of 
hypertension.  A  single  method  was  developed  to  afford  simultaneous 
quantitation  of  actives  and  degradates  for  each  of  the  two  existing 
formulations.  Each  method  is  presented  herein  and  demonstrated  to  be 
suitable for quantitation to 0.1% levels of all relevant degradates, as well as 
100% levels of respective drug substances.
A.G.Butterfield et  al  performed  an  aliquot  of  a  tetrahydrofuran 
extract  of  the  tablet,  containing  polythiazide  as  an  internal  standard,  is 
chromatographed  on a  microparticulate  silica  gel  column using a  mobile 
phase of 0.01% (v/v) diethylamine, 5% (v/v) vhloroform, and 18% (v/v) 2-
propanol in n-hexane.
Erturk S, Cetin SM, Atmaca S. et al developed two new simple and 
selective  assay  methods  have  been  presented  for  the  binary  mixtures  of 
moexipril  hydrochloride  (MOEX)  and  hydrochlorothiazide  (HCTZ)  in 
pharmaceutical formulations. The first method depends on second derivative 
ultraviolet spectrophotometry with zero-crossing measurements at 215 and 
234nm for MOEX and HCTZ, respectively. The assay was linear over the 
concentration ranges 1.0-11.0 micro g ml(-1) for MOEX and 0.5-9.0 microg 
ml(-1) for HCTZ. The second method was based on isocratic reversed phase 
liquid  chromatography  by  using  a  mobile  phase  acetonitrile-20mm 
phosphate buffer (pH 4.0) (50:50, v/v). Lisinopril was used as an internal 
standard (IS) and the substances were detected at 212nm. The linearity range 
for both drugs was 0.5-12.0 microg ml(-1). The determination and detection 
limits were found to be 0.100 and 0.10 microg ml(-1) for MOEX and 0.025 
and 0.005 microg ml(-1) for HCTZ, respectively.
Salem-H et  al  a  new simple,  precise,  accurate  and  selective  high 
performance  thin  layer  chromatographic  (HPTLC)  method  has  been 
developed for the simultaneous determination of five mixtures: atenolol and 
chlorthalidone (Mix. I), enalapril maleate and hydrochlorothiazide (Mix. II), 
amiloride  hydrochloride  and  hydrochlorothiazide  (Mix.  III),  atenolol, 
chlorthalidone  and  amiloride  hydrochloride  (Mix.  IV)  and  atenolol, 
hydrochlorothiazide and amiloride hydrochloride (Mix. V) in bulk powders 
and in pharmaceutical dosage forms. 
Ferraro-MC,  Castellano-PM,  Kaufman-TS et  al  performed  the 
development  and  validation  of  different  chemometric  methods  such  as 
classical  least  squares  principal  components  regression  and  partial  least 
squares with 1 dependent variable applied on UV spectral data and on their 
first  derivatives for  the simultaneous quantification of samples containing 
mixtures  of  amiloride  hydrochloride,  atenolol,  hudrochlorothiazide  and 
timolol maleate, is described.
Erk-N et  al  estimated  two  component  mixtures  of  candesartan 
cilexetil  (CAN)  and  hydrochlorothiazide  (HYD)  were  assayed  by  first 
derivative and ratio derivative spectrophotometry. The first method depends 
on  zero-crossing  and  peak  to  base  measurement.  The  first  derivative 
amplitudes at 270.1 and 255.5nm were selected for the assay of (CAN) and 
(HYD), respectively. The second method depends on first derivative of the 
ratio spectra by division of the absorption spectrum of the binary mixture by 
a normalized spectrum of one of the components and then calculating the 
first derivative of the ratio spectrum.
Ertuerk-S,  Cetin-SM;  Atmaca-S et  al  performed  the  UV 
spectrophotometric  and  isocratic  reversed  phase  liquid  chromatography 
determination  of  binary  mixtures  of  moexipril  hydrochloride  and 
hydrochlorothiazide are evaluated. The methods were successfully applied to 
the  determination  of  moexipril  hydrochloride  and  hydrochlorothiazide  in 
synthetic mixtures and commercially available tablets with a high percentage 
recovery.
Erk-N, Ankara Univ, Fac Pharm et al developed the simultaneous 
determination  of  hydrochlorothiazide  and  irnesartan  in  a  binary  mixture 
without  previous  separation  by  three  new  analytical  methods.  The  first 
method, based on compensation technique, is presented for the derivative 
spectrophotometric  determination  of  binary  mixtures  with  overlapping 
spectra. By using ratios of the derivative maxima or the derivative minimum, 
the  exact  contribution  of  either  component  in  the  binary  mixture  can be 
measured and the amounts quantified. The second method uses of the first 
derivative of the ratio spectra. The ratio spectra were obtained by dividing 
the  absorption  spectra  of  the  binary  mixture  by  that  of  one  of  the 
components. The amplitudes in the first derivative of the ration spectra at 
231,  266,  279,  238  and  248nm  were  selected  to  determine 
hydrochlorothiazide and irbesartan in binary mixtures.
Kamila  MM, Mondal  N, et  al  performed  a  simple,  sensitive  and 
accurate  UV spectrophotometric  method  was  developed  for  the  assay  of 
nebivolol  hydrochloride  in  raw  material  and  tablets.  Validation  of  the 
method  yielded  good  results  concerning  range,  linearity,  precision  and 
accuracy  the  absorbance  was  measured  at  282nm  for  nebivolol 
hydrochloride  tablet  solution.  The  linearity  range  was  found  to  be  5-
50microg/ml for the drug.
B,Dhandapani,  et  al  developed a  simple,  fast,  specific  and precise 
High Performance Thin Layer Chromatographic Method (HPTLC) has been 
developed for estimation of Nebivolol hydrochloride in tablet dosage form. 
The stationary phase silica gel G60F254 was selected for separation and the 
sample  was  developed  using  a  mixture  of  Ethyl  acetate  :  Methanol  : 
Ammonia  in  the  ratio  8.5:1:0.5v/v  as  mobile  phase.  Quantification  was 
carried  out  at  285nm  photometrically.  The  Rf value  of  Nebivolol 
hydrochloride was found to be 0.52 + 0.02. Linearity was found to be in the 
concentration range of 250 to 1250ng/spot of Nebivolol.
Aboul-Enein  HY,  Ali  I.  et  al  performed  studies  on  the  effect  of 
alcohols  on  the  chiral  discrimination  mechanisms  of  amylase  stationary 
phase  on  the  enantioseparation  of  nebivolol  by  HPLC  by  achieving  the 
enantiomeric resolution of (+/-)-nebivolol on Chiralpak AD and Chiralpak 
AD-RH columns with methanol, Ethanol, 1-propanol, 2-propnaol, 1-butanol 
as mobile phases at different flow rates. The (+)-RRRS enantiomer eluted 
first when using methanol, ethanol and 1-propanol, while the elution order 
was reversed when using 2-propanol and 1-butanol as the mobile phases. It 
has been concluded that the reversal elution order observed was due in part 
to the chiral cavities on the amylase CSP which were responsible for the 
bondings  of  different  magnitude  between  chiral  stationary  phase  and 
enantiomers.
Aboul-Enein HY, Ali I. et al performed HPLC enatiomeric resolution 
of  nebivolol  on  normal  and  reversed  amylase  based  chrial  phases.  The 
mobile phases used were pure ethanol and 1-propanol. The flow rates used 
were 0.5, 1.0 and 1.5ml/min. The best resolution was achieved at 0.5ml/min. 
flow rate with ethanol and 1-propanol on both Chiralpak AD and Chiralpak 
AD-RH stationary phases.
K.R.Gupta et  al  developed  a  HPTLC  method  was  developed  for 
analysis of above formulation. Atenolol and indapamide were separated on 
the plate coated with silica gel 60G F254 using a mixture of toluene : ethanol: 
acetone:  acetic  acid  (7:2:5:3:0.3v/v)  as  mobile  phase.  The  Rf value  of 
atenolol and indapamide was found to be 0.21 and 0.74, respectively. The 
percent recovery was found to be 99.2/100.51 and 99.07/98.65% for atenolol 
and indapamide by height by area, respectively.
Suraj P.Agarwal et al developed a new, simple, accurate and precise 
high performance thin layer chromatographic method has been developed for 
the  estimation  of  artemether  and  arteether  as  pure  drug  powder  and  in 
pharmaceutical  formulations.  The  method  employs  silica  gel  F254 as 
stationary phase on aluminium foil  and mobile phase comprising toluene: 
butanol (10:1) in case of artemether and toluene : dichloromethane (0.5:10) 
for arteether. A solution of 10%v/v sulphuric acid in ethanol gave prominent 
well resolved blue coloured spot for artemether and vanillin in sulphuric acid 
in ethanolic solution gave prominent well-resolved pink coloured spot for 
arteether. The Rf values were 0.45 for artemether and 0.30 for arteether.
A.Annerberg et al performed a high throughout bioanalytical assay 
for  the  determination  of  lumefantrine  in  plasma  has  been  developed  and 
validated extensively. The within-day precisions for lumefantrine were 5.2, 
3.5 and 2.5% at 200, 2000 and 15000ng/ml, respectively. The between day 
precisions  were  4.0,  2.8  and  3.1%  at  200,  2000  and  15000ng/ml, 
respectively. The lower limits  of quantification (LLOQ) and the limits  of 
detection (LOD) were 25 and 10ng/ml, respectively using 0.250ml plasma.
N.Lindegardh et  al  estimated  a  bioanalytical  method  for  the 
determination of lumefantrine (LF) and its metabolite desbutyl-lumefantrine 
(DLF) in plasma by solid-phase extraction (SPE) and liquid chromatography 
has been developed.  Plasma proteins were precipitated with acetonitrile : 
acetic  acid  (99:1,  v/v).  The  compounds  were  analysed  by  liquid 
chromatography UV detection on a SB-CN (250mm x 4.6mm) column with 
a  mobile  phase  containing acetonitrile  sodium phosphate  buffer  pH (2.0; 
0.1M)  (55:45,  v/v)  and  sodium  perchlorate  0.05M.  The  limit  of 
quantification was 0.024 and 0.021μg/ml for LF and DLF, respectively.
J.Karbwang,  et  al  developed  a  rapid,  selective,  sensitive  and 
reproducible HPLC with recutive electrochemical detection for quantitative 
determination  of  artemether  (ART)  and  its  plasma  metabolite. 
Chromatographic  separation  was  performed  with  a  mobile  phase  of 
acetonitrile water (20:80, v/v) containing 0.1M acetic acid pH 5.0, running 
through a μBondapak CN column. The minimum detectable concentrations 
for  ART  and  α-DHA  in  spiked  plasma  samples  were  5  and  3ng/ml, 
respectively.  The  method  was  found  to  be  suitable  for  use  in  clinical 
pharmacokinetic study.
S.S.Mohamed,  S.A.Khalid,  S.A.,  et  al  developed  a  sensitive, 
selective  and  reproducible  GC-MS-SIM  Method  was  developed  for 
determination  of  artemether  (ARM)  and  dihydroartemisinin  (DHA)  in 
plasma.  The  analysis  was  carried  out  using  a  HP-5MS  5% 
phenylmethylsiloxane capillary column. The recoveries of ARM, DHA and 
ART were 94.9+1.6%, 92.2+4.1% and 81.3+1.2% respectively. The method 
is currently being used for pharmacokinetic studies.
N.Sandrenan,  et  al  performed  an  analytical  method  for  the 
determination  of  artemether  (A)  and  its  metabolite  dihydroartemisinin 
(DHA) in human plasma has been developed and validated. The method is 
based  on  high-performance  liquid  chromatography  (HPLC)  and 
electrochemical  detection  in  the  reductive  mode.  Chromatography  was 
performed on a Nova-Pak CN, 4μm analytical  column (150mm x 3.9mm 
I.D.)  at  350C. The mobile  phase  consisted  of  pH 5 acetate  – acetonitrile 
(85:15, v/v) at a flow rate of 1ml/min. The mean recovery was 96% at the 
limit of quantitation (LOQ) of 10.9ng/ml with a CV of 13%.
B.M.kotecka,  et al performed a comparison of bioassay and HPLC 
analysis  of  artesunate  (ARTS)  and  dihydroartemisinin  (DHA)  in  plasma. 
ARTS and DHA in plasma samples from patients treated with ARTS were 
quantifed  any HPLC and expressed  as  DHA. Bioassay  of  active  drug in 
plasma correlated well with specific chemical analysis by HPLC. ARTS and 
DHA appear to account for the total anatimalarial activity in plasma after 
ARTS administration.
Himanshu Naik, Daryl J. Murry, et al performed a sensitive method 
has been developed and validated for the determination of artesunate and its 
active  metabolite  dihydroartemisinin  (DHA)  in  human  plasma  using 
artemisinin as an internal standard. Analysis was performed on a Shimadzu 
LCMS-2010. Chromatography was carried out using a Synergi Max-RP, 4μ, 
75mm  x  4.6mm  column  using  glacial  acetic  acid  0.1%,  acetonitrile  and 
methanol mixture (38:46.5:15.5) as a mobile phase delivered at a flow rate of 
0.5ml/min. The retention times of artesunate, α- and β- DHA and artemisinin 
were 17.4, 11.8, 18.7 and 13.4min, respectively.
C.Souppar et  al  developed  a  sensitive  and  selective  method  is 
described  for  the  determination  of  artemether  and  its  active 
dihydroiartemisinin  metabolite  in  human  plasma  using  artemisinin  as 
internal  standard.  Chromatography  was  performed  on  C18 reversed-phase 
column using acetonitrile glacial acetic acid 0.1% (66:34) as a mobile phase. 
The method was fully validated over a concentration range of 5-200ng/ml 
using 0.5ml of human plasma per assay.
M.Rajanikanth,  et  al  developed  a  sensitive  and  selective  assay 
method  for  simultaneous  determination  of  arteether  and  its  metabolite 
dihydroartemisinin  (DHA)  in  rat  plasma  by  liquid  chromatography  mass 
spectrometry.  Chromatographic  separations  were  achieved  by  gradient 
elution of the analytes with an initial  composition of methanol-potassium 
acetate buffer (pH 4; 73:27, v/v) to 100% methanol in 3min and maintained 
for 5min on a Spheri-10, RP18 (100 x 4.6mm i.d.) column following an RP18 
(30 x 4.6mm i.d.) guard column. Linearity in serum was observed over the 
range  4.375-70ng/ml  for  α–arteether  and  10-160ng/ml  for  –arteether  and 
DHA.
M.Bindschedler,  et  al  estimated  co-artemether  is  an  oral  tablet  of 
artemether (20mg) and lumefantrine (120mg) for the treatment of falciparum 
malaria.  Administration  in  the  presence  of  mefloquine  is  likely,  as  co-
artemether  may  be  used  following  failure  of  antimalarial  prophylaxis  or 
treatment with mefloquine. The maximum and average QTc intervals for the 
first,  third  and  sixth  dosing  intervals  of  co-artemether  treatment  were 
compared among treatments. Drug plasma concentrations were determined 
at identical times with the ECG recordings for exploratory pharmacokinetic / 
pharmacodynamic evaluation.
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RESULTS AND DISCUSSION
Pioglitazone, Glimepiride and Metformin:
UV spectrophotometry by simultaneous equation method, RP-HPLC 
and HPTLC method were developed for analyzing Pioglitazone, Glimepiride 
and Metformin in combined tablet dosage form.
For UV spectrophotometry linearity was obtained in the concentration 
range of 5 to 50μg/ml for Glimepiride, 5 to 50μg/ml for Metformin and 5 to 
40μg/ml for Pioglitazone. In quantitative determination the percentage Drug 
content  was  found  to  be  99.54%,  100.07% and 99.33% for  Glimepiride, 
Metformin  and  Pioglitazone  respectively.  Recovery  experiments  were 
performed  and  it  was  within  98-102%,  the  percentage  relative  standard 
deviation were found to be <2% which shows high precision and accuracy of 
the method.
In  HPLC  method,  HPLC  conditions  were  optimized  to  obtain  an 
adequate  separation  of  eluted  compounds.  Initially  various  mobile  phase 
were tried, to separate drugs. Mobile phase and flow rate selection was based 
on peak parameters (height, tailing, theoretical plates, etc). The system with 
buffer (potassium dihydrogen ortho phosphate pH 6): Acetonitile : methanol 
(20:70:10v/v)  with  0.7ml/min  flow  rate  is  quite  robust.  The  optimum 
wavelength for detection was 240nm at which better detector response for 
drugs was obtained. The average retention time for metformin, glimepiride 
and pioglitazone is 3.56, 8.61 and 9.52 min respectively. 
According  to  USP  system  suitability  test  are  an  integral  part  of 
chromatographic method. They are used to verify the reproducibility of the 
chromatographic  system.  To ascertain  its  effectiveness,  system suitability 
tests were carried out on freshly prepared stick solution. The parameters are 
shown in table.           
The  calibration  curve  was  found  to  be  linear  for  the  three  drugs 
namely, Metformin, Pioglitazone and Glimepiride.
The low values of % Relative Standard Deviation indicate the method 
is precise and accurate. The developed method was very specific without the 
interference of excipients.
The  percentage  purity  was  99.8%,  100.35%  and  100.26%  for 
Metformin, Glimepiride and Pioglitazone respectively.
The mean recoveries were found to be in the range of 98% to 102%.
Limit of detection for Metformin, Glimepiride and Pioglitazone was 
found to be 32.98μg/ml, 0.1607μg/ml and 0.1322μg/ml respectively.
Limit  of  quantitation  for  Metformin,  Glimepiride  and  Pioglitazone 
was found to be 99.36μg/ml, 0.4871μg/ml and 0.4007μg/ml respectively.
Robustness of the proposed method was determined by changing the 
pH and flow rate.
Ruggedness  of  proposed  method  was  determined  by  analysis  of 
aliquots from homogenous slot by different analyst in different days using 
similar  operational  environmental  condition.  The  result  were  within  98-
102%.
In HPTLC method, HPTLC conditions were optimized to obtain an 
adequate  separation  of  eluted  compounds.  The  mobile  system (ethanol  : 
ammonia  8:2)  with  0.4μl/spot.  The  average  Rf value  for  metformin, 
pioglitazone and glimepiride is 0.13, 0.44 and 0.61 respectively.
The  calibration  curve  was  found  to  be  linear  for  the  three  drugs 
namely, metformin, pioglitazone and glimepiride.
The low values of % RELATIVE STANDARD DEVIATION indicate 
the method is precise and accurate. The developed method was very specific 
without the interference of excipients. 
The  percentage  purity  was  98.9%,  100.15%  and  100.24%  for 
metformin, pioglitazone and glimepiride respectively.
The mean recoveries were found to be in the range of 98% to 102%.
Limit of detection for Metformin, Glimepiride and Pioglitazone was 
found to be 83.61mcg/ml, 1.48mcg/ml and 1.46mcg/ml respectively. 
Limit  of  quantitation  for  Metformin,  Glimepiride  and  Pioglitazone 
was found to be 253.38mcg/ml, 4.49mcg/ml and 4.5mcg/ml respectively.   
Nebivolol and Hydrochlorothiazide:
Nebivolol  and  Hydrochlorothiazide  in  combined  dosage  form  was 
estimated by simultaneous equation method and absorbance ratio method.
Linearity  was  obtained  in  the  concentration  range  of  10μg/ml  to 
100μg/ml for nebivolol and 10μg/ml to 110μg/ml for hydrochlorothiazide.
The percentage drug content was found to 99.2% for both the drugs 
using simultaneous equation method.
The percentage drug content using absorbance ratio method was found 
to  be  100.11%  and  100.05%  for  nebivolol  and  hydrochlorothiazide 
respectively. 
The recovery experiments were also performed for both method which 
was  within  the  range  of  98-102%  and  showed  <2%  RELATIVE 
STANDARD DEVIATION. This shows the high precision & accuracy of 
the proposed methods.
Lumifantrine and Artemether:
Lumifantrine and Artemether was estimated by simultaneous equation 
method and absorbance ratio method using UV spectrophotometry.
The linearity was obtained in the concentration range of 5 to 50μg/ml 
and 5 to 40μg/ml for Artemether and Lumifantrine respectively. 
The percentage drug content was found to be 99.9% and 99.8% for 
Artemether and Lumifantrine respectively by using simultaneous equation 
method.
The percentage drug content using absorbance ratio method was found 
to be 100.08% and 100.11% for Artemether and Lumifantrine respectively.
The  recovery  experiments  were  performed  for  both  the  methods, 
which were within 98-102% and showed <2% RELATIVE STANDARD 
DEVIATION. This shows the precision & accuracy of the method.
     
SUMMARY AND CONCLUSION
Pioglitazone,  Glimepiride  and  Metformin  available  in  combined 
dosage  form  were  analysed  by  UV-  spectrophotometric  simultaneous 
equation  method,  reverse  phase  high  performance  liquid  chromatography 
and high performance thin layer chromatography.
On comparing all the three methods reverse phase high performance 
liquid chromatography was found to be more accurate, simple and rapid than 
other two methods.
Nebivolol and Hydrochlorothiazide in combined tablet dosage form 
was estimated using UV spectophotometry employing simultaneous equation 
method and absorbance ratio method.
On comparing both the method absorbance ratio method was found to 
be  more  accurate  than  simultaneous  equation  method  for  routine 
simultaneous estimation of both the drugs. The values of standard deviation 
and relative standard deviation were found to be satisfactory.
Lumifentrine  and  Artemether  available  in  combined  tablet  dosage 
form  was  also  estimated  using  UV  spectophotometry  employing 
simultaneous equation method and absorbance ratio method.
On comparing both the method absorbance ratio method was found to 
be  more  accurate  than  simultaneous  equation  method  for  routine 
simultaneous estimation of both the drugs. The values of standard deviation 
and relative standard deviation were found to be satisfactory.   
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